Peter Hoskin

Research interests

Publications

• MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study

  The Lancet Oncology · 2021 · 10.1016/s1470-2045(20)30753-1

• Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30395-x

• The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies

  Clinical and Translational Radiation Oncology · 2018 · https://doi.org/10.1016/j.ctro.2018.01.001

• Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy152

• Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30079-2

• Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1702900

• Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study

  Radiotherapy and Oncology · 2016 · 10.1016/j.radonc.2016.03.011

• Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer

  Radiotherapy and Oncology · 2016 · 10.1016/j.radonc.2016.05.014

• Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1408648

• Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70183-4

• Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

  European Urology · 2014 · 10.1016/j.eururo.2014.09.032

• Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70474-7

• Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1213755

• ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds517

• Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer

  Radiotherapy and Oncology · 2012 · 10.1016/j.radonc.2012.01.007

• ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds517

• Non–Small Cell Lung Cancer: Histopathologic Correlates for Texture Parameters at CT

  Radiology · 2012 · 10.1148/radiol.12112428

• Palliative Radiotherapy for Bone Metastases: An ASTRO Evidence-Based Guideline

  International Journal of Radiation Oncology*Biology*Physics · 2011 · https://doi.org/10.1016/j.ijrobp.2010.11.026

• Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial

  Radiotherapy and Oncology · 2011 · 10.1016/j.radonc.2011.05.013

• Update of the International Consensus on Palliative Radiotherapy Endpoints for Future Clinical Trials in Bone Metastases

  International Journal of Radiation Oncology*Biology*Physics · 2011 · 10.1016/j.ijrobp.2011.02.008

• Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting

  European Urology · 2010 · 10.1016/j.eururo.2010.12.009

• Radiotherapy With Concurrent Carbogen and Nicotinamide in Bladder Carcinoma

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2010.28.4950

• Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study

  JNCI Journal of the National Cancer Institute · 2007 · 10.1093/jnci/djk029

• Evaluation of Five Radiation Schedules and Prognostic Factors for Metastatic Spinal Cord Compression

  Journal of Clinical Oncology · 2005 · 10.1200/jco.2005.04.754

• Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer

  Urology · 2004 · 10.1016/j.urology.2004.01.034

• Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

  The Lancet · 2003 · 10.1016/s0140-6736(03)14110-4

• Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases

  Radiotherapy and Oncology · 1986 · 10.1016/s0167-8140(86)80191-8

Current projects

No projects listed.